Generic Combogesic Availability
Last updated on Apr 10, 2025.
See also: Generic Combogesic IV
Combogesic is a brand name of acetaminophen/ibuprofen, approved by the FDA in the following formulation(s):
COMBOGESIC (acetaminophen; ibuprofen - tablet;oral)
-
Manufacturer: AFT PHARMS US
Approval date: March 1, 2023
Strength(s): 325MG;97.5MG [RLD]
Is there a generic version of Combogesic available?
No. There is currently no therapeutically equivalent version of Combogesic available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Combogesic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Combination composition
Patent 10,532,036
Issued: January 14, 2020
Inventor(s): Atkinson Hartley Campbell
Assignee(s): AFT Pharmaceuticals LimitedA combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol.
Patent expiration dates:
- September 22, 2025✓
- September 22, 2025
-
Pharmaceutical composition containing acetaminophen and ibuprofen
Patent 11,197,830
Issued: December 14, 2021
Inventor(s): Murphy; Maura et al.
Assignee(s): AFT Pharmaceuticals Limited (N/A, N/A)Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 μm, are described.
Patent expiration dates:
- February 27, 2039✓✓
- February 27, 2039
-
Pharmaceutical compostion containing acetominophen and ibuprofen
Patent 11,534,407
Issued: December 27, 2022
Inventor(s): Murphy; Maura et al.
Assignee(s): AFT Pharmaceuticals Limited (N/A, N/A)Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 μm, are described.
Patent expiration dates:
- February 27, 2039✓✓
- February 27, 2039
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 1, 2026 - NEW PRODUCT
More about Combogesic (acetaminophen / ibuprofen)
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- Drug class: analgesic combinations
Patient resources
- Combogesic drug information
- Combogesic (Acetaminophen and ibuprofen Intravenous) (Advanced Reading)
- Combogesic (Acetaminophen/ibuprofen Oral) (Advanced Reading)
- Combogesic (Ibuprofen and acetaminophen Oral) (Advanced Reading)
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.